In 2004 and 2006, the FDA concluded that SSRI antidepressants increased the risk of suicidal ideation in children and adolescents. However, in this month’s Archives of General Psychiatry, Robert Gibbons and four other researchers report that they have re-analyzed the data for Fluoxetine and Venlafaxine, and have concluded that, contrary to the FDA analysis, these two SSRIs do not increase the risk of suicidal behavior in children and adolescents. Three of the five researchers report having received funding from pharmaceutical companies.
Read more Discuss →
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.